AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
KVUE Options Trading: New Contracts Available for August 21st Expiration
ByAinvest
Friday, Jan 2, 2026 10:46 am ET1min read
KVUE--
New options contracts have become available for Kenvue Inc (KVUE) with a focus on the August 21st expiration. The YieldBoost formula has identified a put contract with a current bid of 6 cents and a call contract with a current bid of 91 cents. Investors can sell-to-open these contracts to collect a premium and potentially achieve a higher return than contracts with a closer expiration. The call contract at the $18.00 strike price offers a total return of 9.31% if the stock gets called away at the expiration.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc's editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet